TP53 Y220C mutations in patients with myeloid malignancies

Leuk Lymphoma. 2024 Oct;65(10):1511-1515. doi: 10.1080/10428194.2024.2363440. Epub 2024 Jun 10.

Authors

Georgina Gener-Ricos¹, Jan P Bewersdorf², Sanam Loghavi³, Alex Bataller¹, Aaron D Goldberg², Koji Sasaki⁴, Christopher Famulare², Koichi Takahashi¹, Ghayas C Issa¹, Gautam Borthakur¹, Tapan M Kadia¹, Nicholas J Short¹, Jayastu Senapati¹, Bing Z Carter¹, Keyur P Patel¹, Hagop Kantarjian¹, Michael Andreeff¹, Eytan M Stein², Courtney D DiNardo¹

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Leukemia, UT MD Anderson Cancer Center, Houston, USA.

PMID: 38856690
DOI: 10.1080/10428194.2024.2363440

No abstract available

Keywords: CCUS; CHIP; TP53 mutation; acute myeloid leukemia; myelodysplastic syndromes; myeloid neoplasms.

Publication types

Letter

MeSH terms

Female
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Mutation*
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / genetics
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / genetics
Tumor Suppressor Protein p53* / genetics

Substances

Tumor Suppressor Protein p53
TP53 protein, human